- **Tarsons Products is India’s largest homegrown maker of the plastic consumables that keep laboratories running - the pipette tips, centrifuge tubes and petri dishes scientists use every day - and one of the few Indian labware companies with a genuine global footprint. Founded in 1983, it began as a modest reusable-plastics shop and made an early, defining bet on import substitution, producing India’s first high-quality pipette tips in 1984 and later pioneering the country’s first fully robotic clean-room plant for molecular-biology consumables in 2002. That same pattern - spot a product category dominated by expensive imports, reverse-engineer a high-quality alternative, manufacture it in automated, human-touch-free clean rooms, and sell it on trust rather than price - has governed the company’s expansion for over four decades, most recently into cell-culture and bioprocess products through a large new factory at Panchla.** # Business segments A single engine - plastic labware manufacturing - sold through two distinct channels, domestic distribution and international branded-plus-ODM exports, with a new cell-culture and bioprocess capability entering commercial production. ## 1. Plastic labware manufacturing: the factory engine that makes the products **Tarsons designs, moulds and sells over 2,000 types of plastic consumables and reusables from six vertically integrated plants in West Bengal, competing on consistent quality rather than lowest price.** - **Volume-led, not price-led** - the business grows by selling more units each year, not by raising prices aggressively; the company describes its growth as volume-driven and takes only modest annual price increases to cover inflation. - **Made in human-touch-free clean rooms** - products are manufactured in ISO 8 clean rooms using robotics and automation developed with overseas partners, so the plasticware reaches the lab free of the contaminants that would ruin a PCR experiment or a cell culture. - **Medical-grade resin is the key input** - raw materials account for approx. 20% of revenue, with more than three-quarters sourced from the US and Europe; the company uses high-grade, DMF-registered resins chosen to minimise leachables, and has built relationships with alternative suppliers to guard against disruption. - **A 25% share in the categories it plays in, but only half the market is addressed** - Tarsons holds a quarter of the Indian plastic labware market in the product segments where it is present, yet those segments cover only about 50% of the total market, leaving cell culture, PCR and bioprocess products as the unaddressed opportunity its new Panchla plant is designed to capture. - **Reverse-engineered from proven global designs** - the company takes established labware concepts from global players and redevelops them to match high performance standards while making them cost-accessible to its markets, a method that has built a portfolio of over 2,000 SKUs across 350 product segments. ## 2. Domestic distribution: the trust-based India network **A pan-India network of exclusive, often decades-long distributor relationships, backed by a 50-person direct sales force that stays in constant contact with the scientists at the bench.** - **Exclusive channels that rivals cannot easily share** - the company does not typically share distribution partners with smaller players or multinationals; each competitor in Indian lab consumables tends to operate its own channel, making Tarsons’ network a hard-to-replicate asset. - **Sales force works at the customer level** - 50 dedicated salespeople and regional managers maintain continuous contact with end users, identifying gaps in a lab’s portfolio, building relationships around a specific pain point, and then cross-selling the wider catalogue. - **Brand recognition built over 40 years** - the Tarsons name, along with product brands like Maxipense, Spinwin and Cryochill, carries weight with the scientific community, and the company states it has consistently gained market share even in weak demand environments. - **South and West dominate the map** - the southern region contributes 42% of domestic sales through 40 distributors, and the western region 29% through 23 distributors, with the balance split between the North and East. ## 3. International exports: branded push into emerging markets, ODM for the West **A two-speed export model - selling under the Tarsons brand in Asia Pacific, the Middle East and South America, while supplying white-label ODM products to developed-market customers like Avantor.** - **Branded sales have flipped the mix** - in FY22, branded exports were only 43% of international revenue; by FY26 they had risen to 66%, signalling that the Tarsons name is gaining direct acceptance in more geographies rather than riding on someone else’s label. - **ODM for the US and Europe** - the company designs and develops products to customer specifications and sells them to brand owners such as Avantor, Inc. and Toei Kaisha Limited, who then sell under their own names; this gives Tarsons volume without the cost of building a consumer brand in mature markets. - **45 distributors across 40-plus countries** - international sales are transacted only through distribution partners, never directly with end users; the company meets scientists at 4-6 trade exhibitions each year to build product awareness that pulls demand through those distributors. - **Cost and lead-time advantages over Chinese rivals** - in export markets, Tarsons competes against other Indian exporters and Chinese players on manufacturing cost, process efficiency, shorter lead times and consistent quality, though price competition remains a feature of the landscape. # The Panchla and Amta expansion: a new capability entering production **A large-scale investment programme, nearing completion, that adds cell-culture and bioprocess manufacturing and in-house gamma sterilisation - nearly doubling the addressable market and moving into products with far higher customer stickiness.** - **Panchla opens the cell-culture segment** - the new 21,550 sq. mtr. owned plant began commercial production in November 2024, and the Company is expanding into new product categories and capacity expansion there, including cell-culture flasks, plates, dishes and roller bottles, along with bioprocess and liquid-handling products; these are categories Tarsons had never served before. - **Customer stickiness is much higher in cell culture** - once a lab adopts a particular brand of cell-culture plasticware, switching costs are high because the cells’ behaviour can change with a different surface treatment; Tarsons’ existing 30-40 year relationships with the same user base give it a trust advantage over new entrants. - **Amta brings sterilisation in-house** - the 24,280 sq. mtr. facility includes a gamma radiation processing plant being set up under an MoU with the Government of India’s Board of Radiation and Isotope Technology, reducing dependence on a single external vendor for sterilisation; manufacturing revenue from Amta began in Q4 FY26. - **The whole programme finishes in H1 FY27** - with Panchla and Amta fully commissioned, the company expects its addressable market to nearly double, and a single new warehouse is also being built to streamline inventory across the expanded footprint. # Group structure and partners **A Kolkata-headquartered parent with a Singapore holding subsidiary that owns a German distribution acquisition, plus a government partnership for sterilisation.** - **Tarsons Life Science Pte. Ltd. is the international holding vehicle** - incorporated in Singapore in November 2023 as a wholly-owned subsidiary, it has no operating revenue and exists to hold investments, make acquisitions and form partnerships. - **Nerbe provides a European distribution foothold** - through the Singapore subsidiary, Tarsons acquired 100% of Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG, Hamburg-based distributors of medical and laboratory disposables established in 1976, for approximately €10-15 million in cash; the entities are trading businesses with lower margins than Tarsons’ manufacturing, and the company is working to push its own products through Nerbe’s European network. - **Government partnership for gamma sterilisation** - the MoU with the Board of Radiation and Isotope Technology (BRIT) provides the technology for the Amta gamma processing plant, securing a captive sterilisation capability. - **Promoter-led with strong banking relationships** - the company is chaired by Sanjive Sehgal, with the Sehgal family as promoters, and holds credit ratings of CARE A+ (long-term) and CARE A1+ (short-term) with relationships across HDFC Bank, ICICI Bank, Axis Bank and Federal Bank.